After 20 years of continuous accumulation, Dawnrays Pharmaceutical product development covers the fields of cephalosporin antibiotics, cardiovascular system, endocrine system, digestive system, urinary system, antiviral and anti-allergy drugs, etc., especially the company has established complete product lines in the cephalosporins and cardiovascular systems. In the future, Dawnrays will continue to explore new areas of drug development and enrich the product line in the optimal drugs.

At present, Dawnrays Pharma has the marketed products of cephalosporin APIs, intermediates, injections and oral cephalosporin, etc.. In the future of product planning, Dawnrays Pharmaceutical will expand from “antibiotics field” to “big infection system”. Rallyado™, Entecavir Dispersible Tablets, the anti-virus product produced by Dawnrays Pharmaceutical was issued in markets at home and abroad in 2010. It has been the pioneer for Dawnrays Pharmaceutical to expand the "big infection system"

At present, “An” series antihypertensive drugs produced by Dawnrays have been successfully launched in the markets, of which, "Amlozen"(Amlodipine Besilate Tablets), "An Neixi" (Losartan Potassium and Hydrochlorothiazide Tablets)and "Armotan ™" (Telmisartan Tablets) have become the leading antihypertensive drug brands in China, winning good reputations among doctors and patients in China. Dawnrays will successively develop anticoagulants and anti-lipid drugs in its product planning, expanding from “anti-hypertensive drugs” to “cardiovascular system drugs”.

At present, Dawnrays has launched drugs for stones, diuretics and prostate hyperplasia on the markets. The urinary calculus product "K-CITONE™" (Potassium Citrate Extended-release Tablets) produced by Dawnrays was launched on the market in 2012, and it is the sole chemical drug that can prevent and treat indications of urolithiasis in China. Now, multi-center phase IV clinical trials are under way.

Dawnrays is planning to launch the respiratory and anti-allergy drugs, of which, “CECORIDE™” is a leading anti-allergy drug brand in China; and in its product planning, a new drug for respiratory system will be launched in the future.

After more than 10 years of development, Dawnrays has successfully launched digestive gastric ulcer, gastric mucosal protective agent and antacids, etc. in the field of digestive system drugs. A new drug for digestive system has enter the application and production stages in its product planning.

At present, Dawnrays has launched drugs for diabetes and hyperthyroidism. In its product planning, two drugs for diabetes have entered the clinical trial stage now.